Dare Bioscience DARE Stock News

Daré Bioscience Inc (NASDAQ: DARE) is up more than 10% in the market early on this morning, and for good reason. The company announced positive clinical data from its Sildenafil Cream product candiate. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Is Daré Bioscience?

Daré Bioscience is a clinical-stage biotechnology company. The company’s ultimate goal is to innovate medical products for better women’s health. The company’s products are being developed to improve clinical outcomes and facilitate convenience for women in areas of contraception, vaginal health, sexual health and fertility. It’s product candidates include but are not limited to:

  • Ovaprene – Ovaprene is a non-hormonal, monthly contraceptive intravaginal ring.
  • Sildenafil Cream – Sildenafil Cream is a novel cream formulation of sildenafil. The treatment is under development to as an option for female sexual arousal disorder and uses the same active ingredient as Viagra.
  • DARE-BV1 – DARE-BV1 is a hydrogel formulation of clindamycin phosphate. The product is being developed as an option to treat bacterial vaginosis with a single application.
  • DARE-HRT1 – Finally, we have DARE-HRT1. The treatment is a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause.

DARE Stock Is Rocketing On Positive Clinical Data

As mentioned above, DARE stock is climbing in the market today following the release of positive clinical data. The data came from an investigational study designed to evaluate the feasibility of using thermography technology to assess pharmacodynamics of Sildenafil Cream in a group of healthy women.

Sildenafil is not an uncommon ingredient in sexual arousal disorder treatments. In fact, it is the primary ingredient in Viagra, a treatment indicated for erectile dysfunction in men.

Sildenafil Cream is a topically administered formulation of this active ingredient that is believed to increase local blood flow and provide a potential improvement in genital arousal response and overall sexual experience in women.

In a statement, Martucci Johnson, President and CEO at DARE, had the following to offer:

This study is part of our larger FSAD development program for Sildenafil Cream, and these findings give us greater insight into the physiologic activity and time-to-effect that we should expect to see in the larger studies currently planned for the program.

The Data

In the clinical study, genital temperature was captured and recorded using an infrared cameral capable of detecting heat patterns from blood flow in body tissues. The study was designed to evaluate up to 10 subjects. However, only 6 subjects were enrolled.

In the release, DARE said that primary objectives of the study were reached in the interim analysis of the first 6 subjects. As a result, there will be no further enrollment into the study.

Incredible Potential Ahead

Should all continue to go well in clinical studies, the market potential of the Sildenafil Cream product is incredible. First and foremost, there are no approved therapies for the treatment of sexual arousal dysfunction in women at the moment. So, should the treatment be approved, it will be the ONLY approved option available.

Moreover, estimates suggest that there is a high unmet need for this type of product. In fact, it is suggested that 33% of women in the United States between 21 and 60 years of age experience symptoms of low or no sexual arousal. Moreover, 16% of women (10 million) are actively seeking a solution to improve their condition.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Final Thoughts

Today’s news was overwhelmingly positive for DARE and its investors. After all, the positive clinical data brings the company one step further down the development path for a treatment that could prove to be a blockbuster. Considering the promise of Sildenafil Cream, combined with the other promising candidates in the works, this could be a great long-run play?

What Do You Think?

Where do you think DARE stock is headed moving forward? Join the discussion in the comments below!

Don’t Miss The News Again

Don’t be late to the party! Get real time, actionable alerts delivered directly to your inbox by signing up for our mailing list below!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.